ResMed (NYSE: RMD) announced that it secured a victory in a patent battle with New York University.
The San Diego-based respiratory device maker said the U.S. Patent Trial and Appeals Board (PTAB) invalidated NYU claims against ResMed. These claims came based on seven NYU patents.
In June 2021, NYU filed a complaint for patent infringement against ResMed in the U.S. District Court of Delaware. The complaint alleged that the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringed one or more claims of seven NYU patents.
The company’s AirSense 10 treats sleep apnea. ResMed says AirSense 10 is the world’s most widely used series of CPAP and APAP machines. AutoSet enables the machines to change airflow pressure levels throughout the night based on the user’s needs.
ResMed filed petitions with the PTAB asserting the invalidity of all claims asserted against the company. In rulings issued from Dec. 4 to Dec. 7, 2023, the PTAB judges agreed with ResMed’s arguments. The PTAB found all challenged claims across the seven patents invalid.
Michael Rider, ResMed’s global general counsel and secretary, said the company continues to “vigorously defend” its innovations. He said the victory proved a testament to the company’s R&D investments, plus the work of inventors and the patent protection the company pursues.
“At ResMed, we’re committed to providing patients with our leading therapy solutions,” CEO Mick Farrell said. “Our sustained investment in research and development for over 30 years has culminated in more than 9,500 issued or pending patents and designs. We applaud the PTAB’s ruling and will defend our innovations, ensuring patients continue to receive our therapy solutions, empowering them to live healthier, higher-quality lives.”